Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1644 3792
This examiner grants 78% of resolved cases
Ilia I. Ouspenski is an examiner in Tech Center 3700 and Art Unit 1644 with a history of 1125 resolved cases. The data shows an allowance rate of 77.5 percent, which reflects the outlook for patent applicants in this unit. This volume of 1125 resolved cases suggests a deep experience with the specific technologies handled, providing a baseline for prosecution expectations. Applicants can see that a majority of filings result in a grant.
The interview lift of 20.4 percent suggests that direct engagement with the examiner is an effective strategy for overcoming rejections. This lift is a significant metric for practitioners to consider, as it indicates that verbal communication can improve the 77.5 percent allowance rate. Additionally, the median days to allowance is 972, providing a benchmark for the time required to reach a successful conclusion. The data suggests that while the process takes 972 days, proactive strategies like interviews are statistically supported.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18452395 | BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS | Non-Final OA | Xencor, Inc. |
| 18699108 | ENGINEERED CYTOKINE RECEPTORS FOR TUNABLE ADOPTIVE CELL THERAPY | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18334531 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | Non-Final OA | Genentech, Inc. |
| 18317241 | ANTI-LAG3 ANTIBODIES AND USES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18640092 | COMPOSITIONS AND METHODS OF PHOSPHOLIPASE A2 RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR T CELLS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18317498 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Non-Final OA | JANSSEN PHARMACEUTICALS, INC. |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Non-Final OA | JANSSEN PHARMACEUTICALS, INC. |
| 18490856 | ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS | Non-Final OA | MEDIMMUNE LIMITED |
| 18575628 | UNIVERSAL CAR-T CELL TARGETING IL13RALPHA2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | NINGBO T-MAXIMUM BIOPHARMACEUTICALS CO., LTD. |
| 18037397 | PROTEIN FORMULATIONS AND USES THEREOF | Final Rejection | CSL INNOVATION PTY LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy